Amoozgar, Zohreh
Kloepper, Jonas
Ren, Jun
Tay, Rong En http://orcid.org/0000-0003-3647-9271
Kazer, Samuel W. http://orcid.org/0000-0002-7380-9594
Kiner, Evgeny
Krishnan, Shanmugarajan
Posada, Jessica M.
Ghosh, Mitrajit
Mamessier, Emilie
Wong, Christina
Ferraro, Gino B. http://orcid.org/0000-0002-1587-4259
Batista, Ana
Wang, Nancy
Badeaux, Mark
Roberge, Sylvie
Xu, Lei http://orcid.org/0000-0003-0525-183X
Huang, Peigen http://orcid.org/0000-0002-3184-6493
Shalek, Alex K. http://orcid.org/0000-0001-5670-8778
Fukumura, Dai http://orcid.org/0000-0002-9505-4444
Kim, Hye-Jung http://orcid.org/0000-0001-5595-4264
Jain, Rakesh K. http://orcid.org/0000-0001-7571-3548
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35-CA197743, U01-CA224348, R01-CA208205, P01-CA080124)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 30 January 2021
Accepted: 31 March 2021
First Online: 11 May 2021
Competing interests
: R.K.J. received an honorarium from Amgen; consultant fees from Chugai, Merck, Ophthotech, Pfizer, SPARC, SynDevRx, XTuit; owns equity in Accurius, Elpis, Enlight, and SynDevRx; and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund, and a grant from Boehringer Ingelheim. A.K.S. received compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Cogen Therapeutics and Dahlia Biosciences. No reagents or funding from these organizations was used in this study. The other authors have no competing interests to declare.